These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37407431)

  • 21. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
    Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
    Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP.
    Biswas KH; Sopory S; Visweswariah SS
    Biochemistry; 2008 Mar; 47(11):3534-43. PubMed ID: 18293931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).
    Turko IV; Francis SH; Corbin JD
    J Biol Chem; 1999 Oct; 274(41):29038-41. PubMed ID: 10506154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5.
    Di Rocco G; Martinelli I; Pacifico S; Guerrini R; Cichero E; Fossa P; Franchini S; Cardarelli S; Giorgi M; Sola M; Ponterini G
    J Pharm Biomed Anal; 2018 Feb; 149():335-342. PubMed ID: 29132113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
    Chen G; Wang H; Robinson H; Cai J; Wan Y; Ke H
    Biochem Pharmacol; 2008 May; 75(9):1717-28. PubMed ID: 18346713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP.
    Okada D; Asakawa S
    Biochemistry; 2002 Jul; 41(30):9672-9. PubMed ID: 12135389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
    D'Amours MR; Granovsky AE; Artemyev NO; Cote RH
    Mol Pharmacol; 1999 Mar; 55(3):508-14. PubMed ID: 10051534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity.
    Turko IV; Francis SH; Corbin JD
    Biochemistry; 1998 Mar; 37(12):4200-5. PubMed ID: 9521742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
    Zoraghi R; Corbin JD; Francis SH
    J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).
    Fink TL; Francis SH; Beasley A; Grimes KA; Corbin JD
    J Biol Chem; 1999 Dec; 274(49):34613-20. PubMed ID: 10574925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.
    Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD
    Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
    Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
    Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
    Kayık G; Tüzün NŞ; Durdagi S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of conformational changes and protein-protein interactions of rod photoreceptor phosphodiesterase (PDE6).
    Matte SL; Laue TM; Cote RH
    J Biol Chem; 2012 Jun; 287(24):20111-21. PubMed ID: 22514270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probing domain functions of chimeric PDE6alpha'/PDE5 cGMP-phosphodiesterase.
    Granovsky AE; Natochin M; McEntaffer RL; Haik TL; Francis SH; Corbin JD; Artemyev NO
    J Biol Chem; 1998 Sep; 273(38):24485-90. PubMed ID: 9733741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oligomeric assembly of the phosphodiesterase-5 is a mixture of dimers and tetramers: A putative role in the regulation of function.
    Cardarelli S; Miele AE; Zamparelli C; Biagioni S; Naro F; Malatesta F; Giorgi M; Saliola M
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2183-2190. PubMed ID: 30025857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms.
    Rybalkina IG; Tang XB; Rybalkin SD
    Mol Pharmacol; 2010 Apr; 77(4):670-7. PubMed ID: 20086037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphodiesterase type 5 regulation in the penile corpora cavernosa.
    Lin CS
    J Sex Med; 2009 Mar; 6 Suppl 3():203-9. PubMed ID: 19267844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil.
    Pires de Oliveira I; Lescano CH; De Nucci G
    Chem Biol Drug Des; 2019 Apr; 93(4):419-429. PubMed ID: 30381900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.